MedTrace Logo

Diagnostic Study to Identify Sentinel Lymph Nodes in Women With Stage I or Stage II Breast Cancer

NCT00003654 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2021-02-21

No results posted yet for this study

Summary

RATIONALE: Diagnostic procedures, such as blue dye or imaging to identify sentinel lymph nodes, may improve the ability to detect the extent of disease and help plan effective surgery for removing breast tumors.

PURPOSE: Diagnostic trial to study the effectiveness of blue dye and an imaging procedure to identify the sentinel lymph node under the arm in women with stage I or stage II breast cancer.

Conditions

Interventions

DRUG

patent blue V dye

PROCEDURE

lymphangiography

PROCEDURE

radionuclide imaging

PROCEDURE

sentinel lymph node biopsy

RADIATION

technetium Tc 99m sulfur colloid

Sponsors & Collaborators

  • UNICANCER

    lead OTHER

Principal Investigators

  • Jean-Francois Rodier, MD · Centre Paul Strauss

Study Design

Purpose
DIAGNOSTIC

Eligibility

Min Age
0 Years
Max Age
120 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
1997-09-30
Primary Completion
2000-01-31
Completion
2000-01-31

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00003654 on ClinicalTrials.gov